• TCAIM Modulates Mitochondrial OGDH Levels to Control Metabol

  2026-05-09

  Wang et al. (2025) identify TCAIM as a mitochondrial DNAJC co-chaperone that specifically binds and reduces α-ketoglutarate dehydrogenase (OGDH) protein levels, introducing a novel post-translational regulatory mechanism for mitochondrial metabolism. This finding advances understanding of mitochondrial proteostasis and opens new avenues for metabolic research and targeted intervention.

• ATRA Reverses Cisplatin-Induced PARP Inhibitor Resistance in

  2026-05-09

  This study demonstrates that all-trans retinoic acid (ATRA) effectively sensitizes cisplatin-exposed epithelial ovarian cancer (EOC) cells to PARP inhibition, addressing a key mechanism of drug resistance. The findings reveal that ATRA downregulates resistance-associated genes and NAD+ levels, proposing a rational combination maintenance strategy for EOC therapy.

• ABT-737 in Cancer Research: Precision BCL-2 Inhibition Explo

  2026-05-08

  Explore how ABT-737, a leading BCL-2 protein inhibitor, revolutionizes apoptosis induction in cancer cells. This article uniquely bridges advanced in vitro assay design with practical insights for translational oncology.

• Annexin V-Cy5/DAPI Apoptosis Kit: Precision in Mitochondrial

  2026-05-07

  Explore how the Annexin V-Cy5/DAPI Apoptosis Kit enables precise, rapid apoptosis detection with advanced insight into mitochondrial pathways. This in-depth article connects the latest leukemia research with practical assay optimization, setting a new benchmark for apoptosis detection kits.

• HyperScript™ Reverse Transcriptase: Advanced cDNA Synthesis

  2026-05-07

  HyperScript™ Reverse Transcriptase, engineered from M-MLV Reverse Transcriptase, excels in high-fidelity cDNA synthesis—even from structured or low-abundance RNA. Its unique stability and affinity make it an invaluable tool for challenging qPCR and molecular assays.

• Strategic Caspase-8 Inhibition: Advancing Translational Apop

  2026-05-06

  This thought-leadership article explores how Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone), a specific and potent caspase-8 inhibitor, empowers translational researchers to dissect apoptosis and immune modulation with precision. Integrating mechanistic insights, recent literature, and advanced workflow recommendations, we position Z-IETD-FMK as an indispensable tool for immune cell activation research and T cell proliferation inhibition, while also providing protocol guidance and a strategic outlook informed by new findings in cancer biology.

• A40926 in Translational Research: From MIC to Clinical Insig

  2026-05-06

  Explore how A40926, a potent dalbavancin precursor, bridges in vitro assay data with translational insight for Gram-positive infection and resistance research. This article uniquely analyzes MIC interpretation, regulatory genetics, and practical assay design.

• Prevotella copri Drives Breast Cancer via IPA Depletion and

  2026-05-05

  This study demonstrates that the gut microbe Prevotella copri promotes breast cancer progression by depleting host indole-3-pyruvic acid (IPA), which in turn inactivates the AMPK pathway through UHRF1-mediated regulation. These findings reveal a novel gut microbiota–metabolite–tumor signaling axis and highlight IPA's potential as an intrinsic anti-cancer metabolite.

• HyperFluor™ 488 Goat Anti-Rabbit IgG: Technical Workflow Gui

  2026-05-05

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody is designed for sensitive immunofluorescence, immunocytochemistry, and flow cytometry assays requiring robust signal amplification and minimal cross-reactivity. It is best suited for workflows detecting rabbit primary antibodies in fixed or permeabilized samples. Use caution in direct-conjugate applications or non-rabbit systems, as performance outside the validated scope is not assured.

• SB203580: Precision Control of the p38 MAPK Pathway in Trans

  2026-05-04

  This article synthesizes mechanistic insights and strategic guidance for translational researchers employing SB203580—a selective p38 MAPK inhibitor. By integrating evidence from recent resistance studies and cross-referencing leading thought-leadership content, we offer actionable protocols and visionary perspectives for advancing disease modeling, neuroprotection, and therapeutic resistance research.

• Taltirelin Inhibits Acute and Chronic Itch in Murine Models

  2026-05-04

  The referenced study demonstrates that the thyrotropin-releasing hormone analog Taltirelin robustly suppresses both acute and chronic itch behaviors in mice, with dose-dependent efficacy. These findings expand the known pharmacological actions of Taltirelin and provide a preclinical foundation for its antipruritic potential.

• Nirmatrelvir (PF-07321332): Optimizing SARS-CoV-2 Research W

  2026-05-03

  Nirmatrelvir (PF-07321332) empowers antiviral therapeutics research by enabling selective, reproducible inhibition of SARS-CoV-2 replication. This guide distills evidence-based protocols, troubleshooting insights, and innovations from recent structural studies to help labs maximize the compound’s impact in COVID-19 research.

• Oltipraz: Nrf2 Pathway Activator and Chemopreventive Benchma

  2026-05-02

  Oltipraz is a validated Nrf2 pathway activator and potent phase II enzyme inducer, supporting chemoprevention and xenobiotic detoxification research. Quantitative benchmarks confirm its efficacy in hepatocyte models, with high specificity and reproducibility under defined conditions.

• 3-Methyladenine: Strategic Autophagy Control in Cancer Resea

  2026-05-02

  This thought-leadership article explores the mechanistic and translational value of 3-Methyladenine (3-MA) as a selective autophagy inhibitor, focusing on its dual action on PI3K isoforms, its role in dissecting tumor biology, and evidence from a landmark study on uveal melanoma. We contextualize APExBIO's 3-MA in both experimental design and strategic decision-making for translational researchers, providing actionable protocol guidance and a critical outlook on future clinical opportunities.

• Tariquidar (XR9576): Precision ABC Transporter Inhibition in

  2026-05-01

  Tariquidar (XR9576) provides researchers with a potent, highly selective tool for interrogating P-glycoprotein (P-gp) mechanisms, especially in challenging, high-viscosity tumor microenvironments. Its robust inhibition profile and unique solubility properties make it indispensable for dissecting chemoresistance pathways and optimizing drug disposition assays in cancer research.

455 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page